These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 33875720)

  • 1. Severe allo-immune antibody-associated peripheral and central nervous system diseases after allogeneic hematopoietic stem cell transplantation.
    Hümmert MW; Stadler M; Hambach L; Gingele S; Bredt M; Wattjes MP; Göhring G; Venturini L; Möhn N; Stangel M; Trebst C; Ganser A; Wegner F; Skripuletz T
    Sci Rep; 2021 Apr; 11(1):8527. PubMed ID: 33875720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors influencing overall survival and GvHD development after allogeneic hematopoietic stem cell transplantation - single centre experience.
    Homolová M; Bojtárová E; Kováčová M; Klučková K; Suchánková M; Kušíková M; Mistrík M; Shawkatová I
    Klin Onkol; 2024; 38(2):118-125. PubMed ID: 38697820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
    Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
    Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Noninfectious Neurologic Complications after Allogeneic Hematopoietic Stem Cell Transplantation.
    Balaguer-Rosello A; Bataller L; Piñana JL; Montoro J; Lorenzo I; Villalba A; Freiria C; Santiago M; Sevilla T; Muelas N; Guerreiro M; Carretero C; Gómez I; Solves P; Sanz MÁ; Sanz G; Sanz J
    Biol Blood Marrow Transplant; 2019 Sep; 25(9):1818-1824. PubMed ID: 31132454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Case report: Central nervous system involvement of human graft versus host disease: Report of 7 cases and a review of literature.
    Ruggiu M; Cuccuini W; Mokhtari K; Meignin V; Peffault de Latour R; Robin M; Fontbrune FS; Xhaard A; Socié G; Michonneau D
    Medicine (Baltimore); 2017 Oct; 96(42):e8303. PubMed ID: 29049232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Acute and chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation].
    Barzin A; Geurten C; Willems E; Baron F; Beguin Y; Servais S
    Rev Med Liege; 2022 May; 77(5-6):345-353. PubMed ID: 35657193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurological manifestations of chronic graft-versus-host disease after allogeneic haematopoietic stem cell transplantation: report from the Consensus Conference on Clinical Practice in chronic graft-versus-host disease.
    Grauer O; Wolff D; Bertz H; Greinix H; Kühl JS; Lawitschka A; Lee SJ; Pavletic SZ; Holler E; Kleiter I
    Brain; 2010 Oct; 133(10):2852-65. PubMed ID: 20846944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase I Study of Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Dose Escalation of Targeted Consolidation Immunotherapy with Gemtuzumab Ozogamicin in Children and Adolescents with CD33+ Acute Myeloid Leukemia.
    Zahler S; Bhatia M; Ricci A; Roy S; Morris E; Harrison L; van de Ven C; Fabricatore S; Wolownik K; Cooney-Qualter E; Baxter-Lowe LA; Luisi P; Militano O; Kletzel M; Cairo MS
    Biol Blood Marrow Transplant; 2016 Apr; 22(4):698-704. PubMed ID: 26785332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Transplantation.
    Pavletic SZ; Kumar S; Mohty M; de Lima M; Foran JM; Pasquini M; Zhang MJ; Giralt S; Bishop MR; Weisdorf D
    Biol Blood Marrow Transplant; 2010 Jul; 16(7):871-90. PubMed ID: 20399876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute graft versus host disease in hematopoietic stem cell alotransplant recipients.
    Krstevska S; Genadieva-Stavric S; Pivkova A; Stojanovski Z; Georgievski B; Balkanov T
    Med Arh; 2011; 65(5):260-4. PubMed ID: 22073847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Muscle cramps and neuropathies in patients with allogeneic hematopoietic stem cell transplantation and graft-versus-host disease.
    Kraus PD; Wolff D; Grauer O; Angstwurm K; Jarius S; Wandinger KP; Holler E; Schulte-Mattler W; Kleiter I
    PLoS One; 2012; 7(9):e44922. PubMed ID: 23028681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurological complications in adult allogeneic hematopoietic stem cell transplant patients: Incidence, characteristics and long-term follow-up in a multicenter series.
    Wieczorek M; Mariotto S; Ferrari S; Mosna F; Micò MC; Borghero C; Dubbini MV; Malagola M; Skert C; Andreini A; De Marco B; Polo D; Tfaily A; Krampera M; Grassi A; Candoni A; Ranzato F; Volonghi I; Quatrale R; Benedetti F; Tecchio C
    Bone Marrow Transplant; 2022 Jul; 57(7):1133-1141. PubMed ID: 35513485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Case of Multiple Sclerosis-Like Relapsing Remitting Encephalomyelitis Following Allogeneic Hematopoietic Stem Cell Transplantation and a Review of the Published Literature.
    Das J; Gill A; Lo C; Chan-Lam N; Price S; Wharton SB; Jessop H; Sharrack B; Snowden JA
    Front Immunol; 2020; 11():668. PubMed ID: 32431694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute GVHD is a strong predictor of full donor CD3+ T cell chimerism after reduced intensity conditioning allogeneic stem cell transplantation.
    El-Cheikh J; Vazquez A; Crocchiolo R; Furst S; Calmels B; Castagna L; Lemarie C; Granata A; Ladaique P; Oudin C; Faucher C; Chabannon C; Blaise D
    Am J Hematol; 2012 Dec; 87(12):1074-8. PubMed ID: 22911907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of Epstein-Barr virus associated central nervous system diseases after allogeneic hematopoietic stem cell transplantation with intrathecal donor lymphocyte infusion.
    Zhao J; Zu Y; Han L; Zhang Y; Gui R; Yu F; Li Z; Zhao H; Fang B; Lin Q; Zhou J; Song Y
    Bone Marrow Transplant; 2019 Jun; 54(6):821-827. PubMed ID: 30518982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Allogeneic hematopoietic stem cell transplantations].
    Michallet M
    Transfus Clin Biol; 2011 Apr; 18(2):235-45. PubMed ID: 21466967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute Graft-
    Vinnakota JM; Zeiser R
    Front Immunol; 2021; 12():748019. PubMed ID: 34691059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuronal surface antibody-mediated encephalopathy as manifestation of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
    Pirotte M; Forte F; Lutteri L; Willems E; Duran U; Belle L; Baron F; Beguin Y; Maquet P; Bodart O; Servais S
    J Neuroimmunol; 2018 Oct; 323():115-118. PubMed ID: 30189384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Central nervous system complications after allogeneic hematopoietic stem cell transplantation.
    Chaudhary RK; Dhakal P; Aryal A; Bhatt VR
    Future Oncol; 2017 Oct; 13(25):2297-2312. PubMed ID: 28984145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.